Overview

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Cediranib